[ad_1]
According to The Financial Times, research by PAR and British researchers has shown this.
“Preliminary data from phase I and II studies have shown limited efficacy against mild disease, primarily PAR strain B. 1,351,” an AstraZeneca spokesperson told the publication.
“Oxford University and AstraZeneca have started the process of adapting the vaccine to the strain and will take immediate clinical action so that the vaccine can be developed and distributed in the fall if necessary,” he added.
“We truly believe that our vaccine can protect against serious diseases, since the activity of the neutralizing antibodies is equivalent to that of other COVID-19 vaccines that have been shown to be effective against more severe forms of the disease, especially when the dose range is reduced. optimize for 8-12 weeks, ”the spokesperson said in a statement.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
